Methotrexate and Metformin in Rheumatoid Arthritis Patients
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
Methotrexate (MTX) is the anchor drug for patients with rheumatoid arthritis (RA). Despite
its marked efficacy and acceptable side effect profile, about 1/3 of patients failed to reach
RA remission. Metformin is the first-line therapy for type 2 diabetes. Its antioxidative and
anti-inflammatory properties make it a good candidate for the treatment of inflammatory
diseases such as rheumatoid arthritis.